1-235-Tumor necrosisfactor receptor (human) fusion protein with 236-467-immunoglobulin G1 (human g1-chain Fc fragment) (9CI);1-235-Tumor necrosisfactor receptor (human) fusion protein with 236-467-immunoglobulin G1 (hum...;1-235-Tumor necrosis factor receptor (human) fusion protein with 236-467-immunogl;1-235-Tumor necrosis factor receptor (human) fusion protein with 236-467-immunoglobulin G1 (human gamma1-chain Fc fragment), dimer;Enbrel;Etanercept [USAN];Recombinant human dimeric TNF receptor type II-IgG fusion protein;Recombinant human TNF;rhu TNFR:Fc;TNF receptor type II-IgG fusion protein;TNFR:Fc;TNFR-Fc;TNR 001;UNII-OP401G7OJC;Embrel;Etanercept;Entanercept;rhu-TNFR-Fc;TNFR-Fc fusion protein;rhuTNFR: Fc;1-235-TuMor necrosisfactor receptor (huMan) fusion protein with 236-467-iMMunoglobulin G1 (huMan g1-chain Fc fragMent) (9CI)
Cas No.
185243-69-0
分子式
H4NO3V
分子量
116.98
包装储存
Please store the product under the recommended conditions in the Certificate of Analysis.
Etanercept, a dimeric fusion protein that binds TNF, acts as a TNF inhibitor. Etanercept competitively inhibits the binding of both TNF-α and TNF-β to cell surface TNF receptors, rendering TNF biologically inactive. Etanercept shows efficacy against rheumatoid arthritis, juvenile idiopathic arthritis, and plaque psoriasis.
性状
Liquid
IC50 & Target[1][2]
Fas
体内研究(In Vivo)
Etanercept (10 mg/kg; s.c.; every 3 days for 3 weeks) significantly decreases the mean arthritis scores and radiological score. has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model: Six-wee
储存方式
Please store the product under the recommended conditions in the Certificate of Analysis.
ClinicalTrial
参考文献
[1]. Goffe B, et al. Etanercept: An overview. J Am Acad Dermatol. 2003;49(2 Suppl):S105-S111.[2]. Goldenberg MM. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. Clin Ther. 1999;21(1):75-2.[3]. Haraoui B, et al. Etanercept in the treatment of rheumatoid arthritis. Th